PDCD1 and endometrial cancer: Pembrolizumab, a monoclonal antibody targeting programmed cell death 1(PD-1), was approved for the second-line treatment of metastatic or recurrent endometrial cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) status (3, 4).